Abstract
Home oxygen therapy represents a scientifically validated and universally accepted therapeutic regimen for the treatment of chronic hypoxemia secondary to COPD. The clinical benefits of home oxygen, including a decrease in morbidity and often a concomitant increase in the quality of life have been repeatedly confirmed through rigorous worldwide trials, studies, and investigations. However, since home oxygen is an expensive treatment modality, important questions continue to be raised about the overall cost-benefit of the intervention. Such scrutiny is expected to continue, especially in the United States, as the entire issue of health care cost-containment remains atop the domestic political agenda.
Keywords
Get full access to this article
View all access options for this article.
